ClinicalTrials.gg
CompletedNCT00423657Updated Mar 14, 2017Results posted

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

A Phase 3 interventional study of ceftaroline and vancomycin plus aztreonam in Bacterial Infections, sponsored by Forest Laboratories. Completed at 54 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-14.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
680
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
15th of 151
680 · median 62
Started
2007
with 8 others
Phase 3
24 of 181
2 open now
Registered
25th of 181
by date
Lead sponsor
3 of 181
Forest Laboratories

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 15th largest by enrollment of the 151 interventional ones that give a count, is one of 9 that started in 2007, is one of 24 in phase 3, and was the 25th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.

Read the detailed description

Additional purpose of this study is to compare ceftaroline effectivity versus Vancomycin plus Aztreonam in the treatment of complicated skin infections in adults.

03

Conditions studied

  • Bacterial Infections

Keywords

  • Abscess
  • Antibacterial
  • Antibiotic
  • Antimicrobial
  • Bacterial infection, skin
  • Ceftaroline
  • Ceftaroline acetate
  • Cellulitis
  • Cephalosporin
  • Complicated skin and skin structure infection (cSSSI)
  • cSSSI
  • Intravenous
  • Methicillin-resistant Staphylococcus Aureus (MRSA)
  • PPI-0903
  • Prodrug
  • Skin disease, bacterial
  • Skin infection
  • Staphylococcal skin infection
  • Staphylococcus aureus
  • Streptococcal skin infection
  • Surgical site infection
  • TAK-599
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of current complicated skin and skin structure infection (cSSSI) with an antimicrobial.
  • Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
680 participants (actual)

Study arms

  • Experimental
    Ceftaroline fosamil for Injection

    Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.

    Drug: ceftaroline · Drug: Placebo

  • Active comparator
    IV Vancomycin plus IV Aztreonam

    Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.

    Drug: vancomycin plus aztreonam

Interventions

  • 600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days

    Also known as: Experimental

  • Drugvancomycin plus aztreonam

    Drug pages: VancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AztreonamStudies of AztreonamAztreonam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.

    Also known as: Active Comparator

  • DrugPlacebo

    Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.

06

What researchers measure

Primary outcomes

  1. Clinical Cure Rate at Test of Cure (TOC) (MITT Population)

    Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of complicated skin and skin structure infection (cSSSI) due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI. Indeterminate: Inability to determine an outcome

    Time frame: 8-15 days after last dose of study drug administration

  2. The Primary Efficacy Outcome Measure Was the Per-subject Clinical Cure Rate at the TOC Visit in the Clinically Evaluable (CE) Populations.

    Time frame: 8-15 days after last dose of study drug

Secondary outcomes

  1. To Evaluate the Microbiological Success Rate at the TOC Visit

    Time frame: 8-15 days after the last dose of study drug

  2. To Evaluate the Clinical Response at the End of Therapy (EOT) Visit

    Time frame: last day of study drug administration

  3. To Evaluate the Clinical and Microbiological Response by Pathogen at the TOC Visit

    Time frame: 8-15 days after last dose of study drug

  4. To Evaluate Clinical Relapse at the Late Follow Up (LFU) Visit

    Time frame: 21 to 35 days after the last dose of study drug

  5. To Evaluate Microbiological Reinfection or Recurrence at the LFU Visit

    Time frame: 21-35 days after last dose of study drug

  6. To Evaluate Safety

    Time frame: first study drug dose through TOC

07

Results

Posted Nov 18, 2010

Participant flow

Patients were recruited worldwide from March 2007 to December 2007

Participant flow — Overall Study
MilestoneCeftaroline for InjectionIV Vancomycin Plus IV Aztreonam
Started342338
Completed316313
Not completed2625
Withdrew: Withdrew consent108
Withdrew: Non-compliance01
Withdrew: Other1516
Withdrew: Request of sponsor/investigator10

Outcome measures

PrimaryClinical Cure Rate at Test of Cure (TOC) (MITT Population)

Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of complicated skin and skin structure infection (cSSSI) due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI. Indeterminate: Inability to determine an outcome

Time frame:
8-15 days after last dose of study drug administration
Reported as:
Number · participants
Clinical Cure Rate at Test of Cure (TOC) (MITT Population)
participantsCeftaroline for InjectionIV Vancomycin Plus IV Aztreonam
Clinical Cure291289
Clinical Failure2528
Indeterminate2621
Statistical analysis
  • Ceftaroline for Injection vs IV Vancomycin Plus IV Aztreonam · Risk difference (rd): -0.4 · 95% CI -5.8 to 5.0Risk difference corresponds to Ceftaroline clinical cure rate minus Vancomycin plus Aztreonam clinical cure rate. The confidence interval was calculated using the Miettinen and Nurminen method without adjustment.
PrimaryThe Primary Efficacy Outcome Measure Was the Per-subject Clinical Cure Rate at the TOC Visit in the Clinically Evaluable (CE) Populations.
Time frame:
8-15 days after last dose of study drug

Results for this outcome have not been posted.

SecondaryTo Evaluate the Microbiological Success Rate at the TOC Visit
Time frame:
8-15 days after the last dose of study drug

Results for this outcome have not been posted.

SecondaryTo Evaluate the Clinical Response at the End of Therapy (EOT) Visit
Time frame:
last day of study drug administration

Results for this outcome have not been posted.

SecondaryTo Evaluate the Clinical and Microbiological Response by Pathogen at the TOC Visit
Time frame:
8-15 days after last dose of study drug

Results for this outcome have not been posted.

SecondaryTo Evaluate Clinical Relapse at the Late Follow Up (LFU) Visit
Time frame:
21 to 35 days after the last dose of study drug

Results for this outcome have not been posted.

SecondaryTo Evaluate Microbiological Reinfection or Recurrence at the LFU Visit
Time frame:
21-35 days after last dose of study drug

Results for this outcome have not been posted.

SecondaryTo Evaluate Safety
Time frame:
first study drug dose through TOC

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ceftaroline for Injection—14/341 (4.1%)144/341 (42.2%)
IV Vancomycin Plus IV Aztreonam—16/339 (4.7%)159/339 (46.9%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCeftaroline for InjectionIV Vancomycin Plus IV Aztreonam
AnemiaBlood and lymphatic system disorders0/3411/339
CoagulopathyBlood and lymphatic system disorders0/3411/339
BradycardiaCardiac disorders1/3411/339
Myocardial infarctionCardiac disorders1/3411/339
Sinoatrial blockCardiac disorders0/3411/339
IleusGastrointestinal disorders0/3411/339
Condition aggravatedGeneral disorders0/3411/339
HepatitisHepatobiliary disorders0/3411/339
OsteomyelitisInfections and infestations0/3411/339
PneumoniaInfections and infestations0/3411/339
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCeftaroline for InjectionIV Vancomycin Plus IV Aztreonam
PruritusSkin and subcutaneous tissue disorders13/34128/339
DiarrheaGastrointestinal disorders22/34115/339
NauseaGastrointestinal disorders21/34119/339
HeadacheNervous system disorders18/34118/339
InsomniaPsychiatric disorders12/3418/339
ConstipationGastrointestinal disorders10/34111/339
RashSkin and subcutaneous tissue disorders11/34110/339
VomitingGastrointestinal disorders11/3419/339
HypokalemiaMetabolism and nutrition disorders5/3419/339
AnemiaBlood and lymphatic system disorders4/3418/339

Baseline characteristics

Age, Customized
Age, Customized(participants)Ceftaroline for InjectionIV Vancomycin Plus IV AztreonamTotal
<=18 years000
>18 and < 65 years281291572
>=65 years6147108
Age, Continuous
Age, Continuous(years)Ceftaroline for InjectionIV Vancomycin Plus IV AztreonamTotal
Mean47.8 ± 16.9847.5 ± 16.0747.7 ± 16.52
Sex: Female, Male
Sex: Female, Male(Participants)Ceftaroline for InjectionIV Vancomycin Plus IV AztreonamTotal
Female118137255
Male224201425
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ceftaroline for InjectionIV Vancomycin Plus IV AztreonamTotal
Hispanic or Latino6359122
Not Hispanic or Latino279279558
Unknown or Not Reported000
08

Study locations

54 sites
  • Investigational Site
    Buena Park, California 90620, United States
  • Investigational Site
    Hawaiian Gardens, California 90716, United States
  • Investigational Site
    Los Angeles, California 90033, United States
  • Investigational Site
    Pasadena, California 91105, United States
  • Investigational Site
    San Diego, California 92114, United States
  • Investigational Site
    San Jose, California 95124, United States
  • Investigational Site
    Atlantis, Florida 33462, United States
  • Investigational Site
    Columbus, Georgia 31904, United States
  • Investigational Site
    Marietta, Georgia 30060, United States
  • Investigational Site
    Springfield, Illinois 62701, United States
  • Investigational Site
    Baltimore, Maryland 21201, United States
  • Investigational Site
    Minneapolis, Minnesota 55422, United States
  • Investigational Site
    Butte, Montana 59701, United States
  • Investigational Site
    Somers Point, New Jersey 08244, United States
  • Investigational Site
    Toledo, Ohio 43608, United States
  • Investigational Site
    Tacoma, Washington 98405, United States
  • Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • Investigational Site
    Buenos Aires, Argentina
  • Investigational Site
    Cordoba, Argentina
  • Investigational Site
    Santa Fe, Argentina
  • Investigational Site
    Braunau, Austria
  • Investigational Site
    Graz, 8036, Austria
  • Investigational Site
    St. Polten, 3100, Austria
  • Investigational Site
    Sao Paula, Brazil
  • Investigational Site
    Temuco, Chile
  • Investigational Site
    Valdivia, Chile
  • Investigational Site
    Cottbus, 03048, Germany
  • Investigational Site
    Dortmund, 44145, Germany
  • Investigational Site
    Homburg/Saar, D-66421, Germany
  • Investigational Site
    Mainz, D-55101, Germany
  • Investigational Site
    Wiesbaden, 65191, Germany
  • Investigational Site
    Riga, LV-1001, Latvia
  • Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • Investigational Site
    Seattle Zapopan, Jalisco 45170, Mexico
  • Investigational Site
    Bielsko-Biala, 43-316, Poland
  • Investigational Site
    Krakow, 31-501, Poland
  • Investigational Site
    Kraków, 31-820, Poland
  • Investigational Site
    Lodz, 91-425, Poland
  • Investigational Site
    Lublin, 20-954, Poland
  • Investigational Site
    Poznań, 61-848, Poland
  • Investigational Site
    Warszawa, 02-097, Poland
  • Investigational Site
    Warszawa, 03-401, Poland
  • Investigational Site
    Wroclaw, 50-326, Poland
  • Investigational Site
    Moscow Region, 143405, Russian Federation
  • Investigational Site
    Moscow, 111020, Russian Federation
  • Investigational Site
    Moscow, 119048, Russian Federation
  • Investigational Site
    St. Petersburg, 192242, Russian Federation
  • Investigational Site
    St. Petersburg, Russian Federation
  • Investigational Site
    Kharkov, 61176, Ukraine
  • Investigational Site
    Kyiv, 03110, Ukraine
  • Investigational Site
    Lviv, 79044, Ukraine
  • Investigational Site
    Zaporizhya, 69000, Ukraine
  • Investigational Site
    London, N19 5LW, United Kingdom
  • Investigational Site
    London, SW10 9NH, United Kingdom
09

References and documents

Publications

  • Dryden M, Kantecki M, Yan JL, Stone GG, Leister-Tebbe H, Wilcox M. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials. J Glob Antimicrob Resist. 2022 Mar;28:108-114. doi: 10.1016/j.jgar.2021.10.027. Epub 2021 Dec 16. PubMed 34922058 ↗
  • Wilcox M, Yan JL, Gonzalez PL, Dryden M, Stone GG, Kantecki M. Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials. Infect Dis Ther. 2022 Feb;11(1):217-230. doi: 10.1007/s40121-021-00557-w. Epub 2021 Nov 6. PubMed 34741280 ↗
  • Corey GR, Wilcox MH, Gonzalez J, Jandourek A, Wilson DJ, Friedland HD, Das S, Iaconis J, Dryden M. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. Int J Antimicrob Agents. 2019 Jun;53(6):830-837. doi: 10.1016/j.ijantimicag.2019.01.016. Epub 2019 Feb 1. PubMed 30716446 ↗
  • Cheng K, Pypstra R, Yan JL, Hammond J. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. J Antimicrob Chemother. 2019 Apr 1;74(4):1086-1091. doi: 10.1093/jac/dky519. PubMed 30597021 ↗
  • Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv67-iv71. doi: 10.1093/jac/dkq256. PubMed 21115456 ↗
  • Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 2 investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv53-iv65. doi: 10.1093/jac/dkq255. PubMed 21115455 ↗
  • Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827. PubMed 20695801 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2007
First posted
Jan 18, 2007
Start
Mar 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Nov 18, 2010
Last update
Mar 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00423657
First posted
Jan 18, 2007
Start date
Mar 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Nov 18, 2010
Last update
Mar 14, 2017

Study contacts

Mark Wilcox, MD
principal investigator · Old Medical School

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftaroline

Start the discussion